Next-Generation GLP-2 Analogs

Teduglutide requires daily subcutaneous injection, creating a significant treatment burden. Two long-acting GLP-2 analogs are in late-stage clinical development:

Glepaglutide (Zealand Pharma): A GLP-2 analog with multiple backbone modifications conferring a plasma half-life of approximately 50 hours, enabling weekly subcutaneous dosing. The phase 3 EASE SBS trial demonstrated significant reductions in parenteral support volume with weekly glepaglutide compared to placebo, with a safety profile similar to teduglutide. Glepaglutide also showed efficacy in patients who had previously failed teduglutide.

Apraglutide (VectivBio, acquired by Ironwood Pharmaceuticals): A GLP-2 analog with a half-life of approximately 30 hours, also designed for weekly dosing. Phase 2 data demonstrated dose-dependent reductions in PN volume in SBS patients, with the highest dose (10 mg weekly) achieving median PN reductions comparable to daily teduglutide. Phase 3 trials are ongoing.

DPP-IV Degradation and Pharmacological Strategies

The rapid inactivation of native GLP-2 by DPP-IV is the central pharmacological challenge in GLP-2 therapeutics. DPP-IV (also known as CD26) is a serine protease expressed on the surface of endothelial cells, T lymphocytes, and intestinal epithelial cells. It cleaves dipeptides from the N-terminus of peptides with alanine or proline at position 2. For GLP-2, this generates the inactive fragment GLP-2(3-33) with a half-life of degradation of approximately 7 minutes.

Three strategies have been employed to overcome DPP-IV degradation:

1. Position 2 substitution (teduglutide: Ala→Gly) — reduces but does not eliminate DPP-IV susceptibility
2. Backbone engineering (glepaglutide, apraglutide) — multiple substitutions creating peptides with dramatically extended half-lives
3. DPP-IV inhibitors (sitagliptin, vildagliptin) — systemic DPP-IV inhibition increases endogenous GLP-2 levels, though the magnitude of increase is modest and the therapeutic impact on intestinal growth is less than exogenous GLP-2 analog administration

Parenteral Nutrition Reduction

The clinical impact of GLP-2 analogs is measured primarily by reduction in parenteral nutrition requirements. PN is life-saving for SBS patients but carries significant complications: central line infections (catheter-related bloodstream infections, CRBSI), intestinal failure-associated liver disease (IFALD), metabolic bone disease, renal impairment, venous thrombosis, and profound reduction in quality of life. Each day of PN eliminated represents meaningful clinical benefit.

In long-term teduglutide studies, approximately 10-15% of patients achieved complete enteral autonomy (full PN independence), and the majority achieved clinically meaningful reductions in PN volume and infusion frequency. This enables fewer infusion nights per week, reduced catheter dwell time, and lower CRBSI risk. Schwartz et al. (2016)

Intestinal Adaptation

GLP-2 analogs promote intestinal adaptation — the physiological process by which the remnant bowel increases its absorptive capacity following resection. Adaptation involves villus elongation, crypt deepening, intestinal dilation, and slowing of transit. GLP-2 amplifies and accelerates this process through its trophic, anti-apoptotic, and blood flow effects.

Serial intestinal biopsies in teduglutide-treated patients confirm structural adaptation: villus height increases by 20-40%, crypt depth increases proportionally, and the absorptive surface area of the remnant bowel expands significantly. These changes are sustained as long as treatment continues and may partially persist after treatment discontinuation, suggesting that GLP-2 facilitates permanent structural remodeling in some patients. Tappenden (2014)

GLP-2 in Critical Illness and Chemotherapy

GLP-2 receptor agonists are being investigated for chemotherapy-induced mucositis and radiation enteritis, conditions where cytotoxic damage to the rapidly dividing crypt epithelium leads to mucosal breakdown, diarrhea, bacterial translocation, and sepsis. In rodent models, teduglutide administered before or concurrent with chemotherapy reduces mucosal injury, preserves crypt cell viability, and accelerates mucosal recovery. These findings have implications for cancer supportive care.

Short Bowel Syndrome (Teduglutide)

The pivotal STEPS trial demonstrated that teduglutide (0.05 mg/kg/day SC) significantly reduced parenteral nutrition volume requirements in adults with SBS-intestinal failure. After 24 weeks, 63% of teduglutide-treated patients achieved a clinically meaningful reduction (>20%) in parenteral support volume, compared to 30% of placebo-treated patients. Extended follow-up studies showed that continued teduglutide treatment for up to 30 months enabled progressive reductions in PN requirements, with some patients achieving complete independence from parenteral support (enteral autonomy). The response reflects genuine intestinal adaptation — increased villus height, crypt depth, and absorptive surface area in the remnant bowel. Jeppesen et al. (2012) — Gut

Pediatric Short Bowel Syndrome

Teduglutide was approved for pediatric SBS in 2019 based on a phase 3 study demonstrating significant reductions in parenteral support in children aged 1-17 years. Pediatric SBS is particularly important because intestinal failure-associated liver disease (IFALD) is a leading cause of morbidity and mortality in this population, and reducing PN dependence directly mitigates IFALD risk. The pediatric response rate was consistent with adult data, with the majority of patients achieving clinically meaningful PN volume reductions. Intestinal adaptation in children may be even more robust than in adults due to the greater growth and adaptation potential of the developing intestine. Kocoshis et al. (2020) — J. Pediatr. Gastroenterol. Nutr.

Inflammatory Bowel Disease

GLP-2 and its analogs have been investigated in inflammatory bowel disease (IBD) based on their mucosal-protective properties. In experimental models of colitis, GLP-2 administration reduced mucosal inflammation, preserved barrier integrity, and enhanced mucosal repair. Clinical studies in Crohn's disease patients showed that teduglutide improved Crohn's Disease Activity Index (CDAI) scores and promoted mucosal healing. However, clinical development for IBD has been less actively pursued than for SBS, partly due to theoretical concerns about promoting epithelial proliferation in a disease with increased colorectal cancer risk. Drucker et al. (1999) — Am. J. Physiol.

Chemotherapy and Radiation-Induced Intestinal Injury

GLP-2 has demonstrated protective effects against chemotherapy-induced mucositis and radiation enteritis in preclinical models. Administration of GLP-2 analogs before or during cytotoxic therapy reduces villus atrophy, crypt destruction, and mucosal inflammation, and accelerates recovery of the intestinal epithelium. The mechanism involves both the anti-apoptotic effects on crypt stem cells and the proliferative stimulus to surviving crypt cells. These findings position GLP-2 analogs as potential supportive care agents for cancer patients experiencing severe GI toxicity from chemotherapy or abdominal/pelvic radiation. Booth et al. (2004) — Cancer Res.

Next-Generation Analogs

Glepaglutide (ZP1848, Zealand Pharma) is a long-acting GLP-2 analog with a half-life of approximately 50 hours, enabling once-weekly or less frequent dosing. Phase 3 results (EASE SBS 1 and 2 trials) demonstrated significant reductions in parenteral support requirements. Apraglutide (FE 203799, VectivBio/Ironwood) is another long-acting GLP-2 analog with a half-life of approximately 30 hours, designed for weekly subcutaneous dosing. Phase 3 trials (STARS program) are evaluating apraglutide in SBS-intestinal failure. Both agents aim to improve patient convenience and compliance compared to daily teduglutide injections while maintaining or improving efficacy. Hvistendahl et al. (2022) — Lancet Gastroenterol. Hepatol.

Short Bowel Syndrome — Teduglutide Clinical Trials

The clinical development of teduglutide for SBS represents the definitive translational success of GLP-2 biology. SBS results from extensive surgical resection of the small intestine (Crohn's disease, mesenteric ischemia, volvulus, NEC, trauma) and leads to intestinal failure — the inability to absorb sufficient nutrients and fluids to sustain health without parenteral nutrition (PN).

STEPS trial (Study of Teduglutide Effectiveness in Parenteral Nutrition-dependent Short Bowel Syndrome): The pivotal phase 3 trial randomized 86 adult SBS patients to teduglutide 0.05 mg/kg/day SC or placebo for 24 weeks. The primary endpoint — a 20-100% reduction in weekly PN volume — was achieved by 63% of teduglutide patients versus 30% of placebo patients (p=0.002). Mean PN volume reduction was 4.4 L/week with teduglutide versus 2.3 L/week with placebo. Citrulline levels (a biomarker of functional enterocyte mass) increased significantly, confirming genuine intestinal adaptation. Jeppesen et al. (2012)

STEPS-2 and STEPS-3 extensions: Extended treatment for up to 30 months demonstrated progressive, sustained reductions in PN requirements. Some patients achieved complete enteral autonomy (independence from PN). The long-term response reflects genuine intestinal adaptation — villus elongation and increased absorptive surface area — rather than transient fluid shifts.

Pediatric SBS: Teduglutide was approved for pediatric SBS (ages 1-17) in 2019 based on a phase 3 study showing PN volume reductions consistent with adult data. Pediatric SBS is particularly critical because intestinal failure-associated liver disease (IFALD) is a leading cause of morbidity and mortality, and reducing PN dependence directly mitigates IFALD risk. Kocoshis et al. (2020)

Intestinal Barrier and Permeability

GLP-2's ability to reduce intestinal permeability has generated interest in conditions characterized by "leaky gut" — increased paracellular permeability to luminal antigens and bacteria. In animal models, GLP-2 strengthened the tight junction barrier, reduced bacterial translocation, and attenuated the systemic inflammatory response to intestinal injury. In humans with SBS, teduglutide reduced citrulline-adjusted intestinal permeability, indicating genuine improvement in barrier function. These findings have implications for conditions beyond SBS where barrier dysfunction contributes to pathology, including IBD, celiac disease, and critical illness. Benjamin et al. (2000) — Gut